

MYLAN LABORATORIES INC

Form 8-K

April 05, 2004

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION**

**WASHINGTON, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT  
PURSUANT TO SECTION 13 OR 15 (d) OF  
THE SECURITIES EXCHANGE ACT OF 1934**

Date of Report (Date of earliest event reported): **April 2, 2004**

**MYLAN LABORATORIES INC.**

(Exact name of registrant as specified in its charter)

<b>Pennsylvania</b> (State or other jurisdiction of incorporation Number)	<b>1-9114</b> (Commission File Number)	<b>25-1211621</b> (I.R.S. Employer Identification No.)
---	--	--

**1500 Corporate Drive  
Canonsburg, PA 15317**  
(Address of principal executive offices)

**(724) 514-1800**  
(Registrant's telephone number, including area code)

---

**Item 5. Other Events and Regulation FD Disclosure.**

On April 2, 2004, correspondence was submitted to the FDA on behalf of Mylan Laboratories Inc. (the Company), with regard to the Company's generic transdermal fentanyl product, in response to correspondence submitted on behalf of Alza Corporation. Copies of such correspondence are attached hereto as Exhibits 99.1 and 99.2.

**Item 7. Financial Statements and Exhibits.**

(c) Exhibits.

<u>Exhibit No.</u>	<u>Description</u>
99.1	Letter to the FDA submitted on behalf of the Company, dated April 2, 2004.
99.2	Letter to the FDA submitted on behalf of the Alza Corporation, dated March 31, 2004.

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: April 2, 2004

MYLAN LABORATORIES INC.

By: /s/ Robert J. Coury

Robert J. Coury  
Vice Chairman and Chief Executive Officer

---

**EXHIBIT INDEX**

<u>Exhibit No.</u>	<u>Description</u>
99.1	Letter to the FDA submitted on behalf of the Company, dated April 2, 2004.
99.2	Letter to the FDA submitted on behalf of the Alza Corporation, dated March 31, 2004.